Retrospective Evaluation of Toceranib Phosphate (Palladia®) in Treatment of Feline Pancreatic Carcinoma
2021 VCS Annual Conference

Carlos Ortiz Rosario1; Margaret Musser1; Jonathan Mochel1; Erika Berger1; Jessica Talbott2; Chad Johannes1

1College of Veterinary Medicine, Iowa State University, Ames, IA, USA; 2Angell Animal Medical Center, Boston, MA, USA


Introduction

Feline exocrine pancreatic carcinoma is a rare cancer with generally poor prognosis in cats. Historical management has included surgery and/or injectable chemotherapy. The primary aim of this study was to evaluate the biological response in cats with pancreatic carcinoma treated with toceranib phosphate (TP). As a secondary aim, the progression free interval (PFI) and median survival time (MST) were calculated. Adverse events following treatment with TP were also evaluated.

Methods

A multi-institutional retrospective study was performed. For inclusion, cats were required to have a confirmed diagnosis of exocrine pancreatic carcinoma either by histopathology, cytology, or both, and to have received treatment with TP.

Results

Twenty-nine cats from 15 institutions were included. Twenty cats were treated for gross disease, six for microscopic/incomplete margins, two in a rescue setting, and one for maintenance after completing chemotherapy. Eleven (38%) cats had documented metastatic disease at time of diagnosis. Six cats received chemotherapy (carboplatin [five], cyclophosphamide [one]) prior to TP. One cat received chlorambucil concurrent with TP. Response data were available in 26 cats. Clinical benefit (CR, PR, SD>10 weeks) was observed in 13/26 (50%; CR=3; SD=10). Adverse events (AEs) were observed in 9/29 (31%) of cats. Most AEs were low grade (VCOG) and successfully managed with supportive care and/or dose adjustments.

Conclusion

Although feline exocrine pancreatic carcinoma continues to be a difficult disease to treat, TP appears to provide clinical benefit. Prospective studies are warranted to further evaluate the potential clinical utility of TP in management of this cancer.

 

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Carlos Ortiz Rosario
College of Veterinary Medicine
Iowa State University
Ames, IA, USA


MAIN : Resident Poster Abstracts : Toceranib in Feline Pancreatic Carcinoma
Powered By VIN
SAID=27